[go: up one dir, main page]

PE20090487A1 - Compuestos heterociclos como inhibidores de lta4h - Google Patents

Compuestos heterociclos como inhibidores de lta4h

Info

Publication number
PE20090487A1
PE20090487A1 PE2008000325A PE2008000325A PE20090487A1 PE 20090487 A1 PE20090487 A1 PE 20090487A1 PE 2008000325 A PE2008000325 A PE 2008000325A PE 2008000325 A PE2008000325 A PE 2008000325A PE 20090487 A1 PE20090487 A1 PE 20090487A1
Authority
PE
Peru
Prior art keywords
compounds
phenoxy
etoxy
benzoxazole
lta4h
Prior art date
Application number
PE2008000325A
Other languages
English (en)
Inventor
William T Barchuk
Paul J Dunford
James P Edwards
Anne M Fourie
Lars Karlsson
Joanne M Quan
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39686382&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20090487(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of PE20090487A1 publication Critical patent/PE20090487A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

REFERIDA A COMPUESTOS DERIVADOS DE FORMULA (I) DONDE X ES S, N O NR5, DONDE R5 ES H O CH3; Y ES O O CH2; Z ES O O UN ENLACE; W ES CH2 O CHR1-CH2, DONDE R1 ES OH O H; R4 ES H, OCH3, Cl, F, Br, I, OH, NH2, CN, CF3 O CH3; R6 ES H O F; R2 Y R3 SON INDEPENDIENTEMENTE H, ALQUIL(C1-C7), CICLOALQUENILO(C5-C7), CICLOAQUIL(C3-C7) OPCIONALMENTE BENZOFUSIONADO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 2-[4-(2-PIRROLIDIIN-1-IL-ETOXI)-FENOXI]-BENZOXAZOL; {3-[4-(BENZOXAZOL-2-ILOXI)-FENOXI]-PROPIL}-DIMETIL-AMINA; 2-[4-(2-AZEPAN-1-IL-ETOXI)-FENOXI]-BENZOXAZOL, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON INHIBIDRORES DE LA ENZIMA LEUCOTRIENO A4 HIDROLASA (LTA4H) SIENDO UTILES EN EL TRATAMIENTO DE ENFERMEDADES ASOCIADAS A LA INFLAMACION
PE2008000325A 2007-02-14 2008-02-14 Compuestos heterociclos como inhibidores de lta4h PE20090487A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US88985107P 2007-02-14 2007-02-14

Publications (1)

Publication Number Publication Date
PE20090487A1 true PE20090487A1 (es) 2009-05-16

Family

ID=39686382

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008000325A PE20090487A1 (es) 2007-02-14 2008-02-14 Compuestos heterociclos como inhibidores de lta4h

Country Status (7)

Country Link
US (1) US20080194630A1 (es)
AR (1) AR065355A1 (es)
CL (1) CL2008000468A1 (es)
PE (1) PE20090487A1 (es)
TW (1) TW200906396A (es)
UY (1) UY30918A1 (es)
WO (1) WO2008100564A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2313079T3 (es) * 2003-07-28 2009-03-01 Janssen Pharmaceutica Nv Benzimidazol, benzotiazol, benzoxazol y su utilizacion como moduladores de lta4h.
PT2336125E (pt) * 2008-04-11 2013-03-18 Janssen Pharmaceutica Nv Tiazolopiridina-2-iloxi-fenil e tiazolopirazin-2-iloxifenil aminas como moduladores de leucotrieno a4 hidrolase
US20110257225A1 (en) * 2008-10-27 2011-10-20 M's Science Corporation Cyclohexylamine derivative containing phenyl group, and therapeutic agent for diseases accompanied by central nervous system disorders
PE20120578A1 (es) * 2009-02-10 2012-06-17 Abbott Lab Agonistas y antagonistas del receptor de s1p5, y metodos de uso de los mismos
WO2010132599A1 (en) * 2009-05-14 2010-11-18 Janssen Pharmaceutica Nv Compounds with two fused bicyclic heteroaryl moieties as modulators of leukotriene a4 hydrolase
CN103483209A (zh) * 2013-09-13 2014-01-01 陕西嘉禾植物化工有限责任公司 一种大麦碱的合成方法
DK3083564T3 (en) 2013-12-20 2018-10-22 Novartis Ag Heteroberl butyric acid derivatives as LTA4H inhibitors
WO2016100823A1 (en) 2014-12-19 2016-06-23 The Broad Institute, Inc. Dopamine d2 receptor ligands
WO2016100940A1 (en) 2014-12-19 2016-06-23 The Broad Institute, Inc. Dopamine d2 receptor ligands
KR20180107142A (ko) 2016-02-11 2018-10-01 바이엘 크롭사이언스 악티엔게젤샤프트 해충 방제제로서의 치환된 2-옥시이미다졸릴-카르복스아미드
AU2020207638B2 (en) * 2019-01-11 2023-04-13 Novartis Ag LTA4H inhibitors for the treatment of Hidradenitis Suppurativa
WO2020146822A1 (en) * 2019-01-11 2020-07-16 Naegis Pharmaceuticals Inc. Leukotriene synthesis inhibitors
US11932630B2 (en) * 2021-04-16 2024-03-19 Novartis Ag Heteroaryl aminopropanol derivatives
CN113683491A (zh) * 2021-09-01 2021-11-23 王传良 一种4-(2-溴乙基)苯酚的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873346A (en) * 1985-09-20 1989-10-10 The Upjohn Company Substituted benzothiazoles, benzimidazoles, and benzoxazoles
CA1319144C (en) * 1986-11-14 1993-06-15 Quirico Branca Tetrahydronaphthalene derivatives
IT1240598B (it) * 1990-03-13 1993-12-17 Mini Ricerca Scient Tecnolog Derivati amminici ad azione antifungina
US5889006A (en) * 1995-02-23 1999-03-30 Schering Corporation Muscarinic antagonists
IL117149A0 (en) * 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
ES2313079T3 (es) * 2003-07-28 2009-03-01 Janssen Pharmaceutica Nv Benzimidazol, benzotiazol, benzoxazol y su utilizacion como moduladores de lta4h.
PL1863476T3 (pl) * 2005-03-16 2016-07-29 Meda Pharma Gmbh & Co Kg Skojarzenie środków antycholinergicznych i antagonistów receptora leukotrienowego do leczenia chorób układu oddechowego

Also Published As

Publication number Publication date
WO2008100564A1 (en) 2008-08-21
UY30918A1 (es) 2008-09-02
CL2008000468A1 (es) 2008-08-22
TW200906396A (en) 2009-02-16
AR065355A1 (es) 2009-06-03
US20080194630A1 (en) 2008-08-14

Similar Documents

Publication Publication Date Title
PE20090487A1 (es) Compuestos heterociclos como inhibidores de lta4h
PE20080951A1 (es) DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS
PE20091466A1 (es) Derivados de 4,5-dihidro-oxazol-2-il-amina
PE20081532A1 (es) Compuestos novedosos
PE20110308A1 (es) 1,2,5-oxadiazoles como inhibidores de indolamina 2,3-dioxigenasa
PE20050691A1 (es) Proceso para preparar carboxamidas 2-aminotiazol-5-aromaticas como inhibidores de la cinasa
PE20121050A1 (es) Compuestos de n-(1-(4-(1h-pirazol-5-il)ftalazin-1-il)piperidin-4-il)-benzamida sustituidos como antagonistas de la trayectoria hedgehog
PE20090617A1 (es) Compuestos amino-5-[-4-(difluorometoxi)fenil]-5-fenilimidazolona para la inhibicion de -secretasa
PE20110433A1 (es) Antagonistas de la via hedgehog de ftalazina disustituida
PE20090210A1 (es) Compuestos derivados de pirazolo pirimidina como inhibidores de jak quinasa
PE20080948A1 (es) Derivados de imidazol como moduladores de la senda de hedgehog
PE20141375A1 (es) Activadores de glucoquinasa
PE20090601A1 (es) Derivados de piridin-il-oxi-piridinas como inhibidores de alk5
PE20130405A1 (es) Compuestos de pirazol-4-il-heterociclil-carboxamida y metodos de uso
PE20071322A1 (es) Derivados de 2-morfolinopirimidina como inhibidores de fosfatidinoinositol(pi) 3-quinasa
PE20110150A1 (es) Amidofenoxiindazoles como inhibidores de c-met
PE20121500A1 (es) 2-amino-5,5-difluor-5,6-dihidro-4h-oxazinas como inhibidores de bace 1 y/o bace 2
PE20110061A1 (es) Derivados de diamino-piridina, pirimidina y piridazina como moduladores del receptor h4 de histamina
PE20091656A1 (es) Compuestos heterociclicos como inhibidores de la cinasa raf
PE20060525A1 (es) Compuestos heterociclicos como inhibidores de cetp
PE20070461A1 (es) Compuestos de amino-5-[4-(difluorometoxi)fenil]-5-fenilimidazolona como inhibidores de b-secretasa
PE20141700A1 (es) Compuestos de 2-(2,4,5-anilino sustituido) pirimidina
PE20141203A1 (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
PE20140868A1 (es) Antagonistas trpm8 y su uso en tratamientos
PE20061198A1 (es) Derivados de pirazol como inhibidores de cdk y gsk

Legal Events

Date Code Title Description
FD Application declared void or lapsed